Raltegravir,alsoknownasMK-0518,isanantiretroviraldrugusedtotreatHIVinfection.Raltegravirisahumanimmunodeficiencyvirus(HIV)integrasestrandtransferinhibitor(HIV-1INSTI)withHIV-1antiviralactivity.Raltegravirbindstoandinhibitsintegrase,anHIVenzymethatinsertsviralgeneticmaterialintothegeneticmaterialoftheinfectedhumancell.InhibitionofintegrasepreventsinsertionofHIVDNAintothehumanDNAgenome,thusblockingHIVreplication.ItreceivedapprovalbytheU.S.FoodandDrugAdministration(FDA)inOctober2007,thefirstofanewclassofHIVdrugs,theintegraseinhibitors,toreceivesuchapproval.

MedKooCat#:300210
Name:Raltegravirpotassium
CAS#:871038-72-1(potassiumsalt)
ChemicalFormula:C20H20FKN6O5
ExactMass:444.15575
MolecularWeight:482.5137
ElementalAnalysis:C,49.79;H,4.18;F,3.94;K,8.10;N,17.42;O,16.58


Synonym:MK0518;MK0518;MK-0518;HSDB-8124;HSDB8124;HSDB8124;Raltegravir;brandname:Isentress

IUPAC/ChemicalName:potassium4-((4-fluorobenzyl)carbamoyl)-1-methyl-2-(2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl)-6-oxo-1,6-dihydropyrimidin-5-olate

SMILESCode:O=C(C(N=C(C(NC(C1=NN=C(C)O1)=O)(C)C)N2C)=C([O-])C2=O)NCC3=CC=C(F)C=C3.[K+]


TechnicalData

Appearance:
solidpowder

Purity:
>98%(orrefertotheCertificateofAnalysis)

ShippingCondition:
Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.

StorageCondition:
Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:
SolubleinDMSO.

ShelfLife:
>2yearsifstoredproperly

DrugFormulation:
ThisdrugmaybeformulatedinDMSO

StockSolutionStorage:
0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:
293490


AdditionalInformation

RelatedCAS#
518048-05-0(Raltegravirfree);
871038-72-1(Raltegravirpotassiumsalt)


References

 1:CalcagnoA,D'AvolioA,BonoraS.PharmacokineticandpharmacodynamicevaluationofraltegravirandexperiencefromclinicaltrialsinHIV-positivepatients.ExpertOpinDrugMetabToxicol.2015Jul;11(7):1167-76.doi:10.1517/17425255.2015.1056732.Review.PubMedPMID:26073580.

2:RipamontiD,BenattiSV,DiFilippoE,RavasioV,RizziM.Drugreactionwitheosinophiliaandsystemicsymptomsassociatedwithraltegraviruse:casereportandreviewoftheliterature.AIDS.2014Apr24;28(7):1077-9.doi:10.1097/QAD.0000000000000204.Review.PubMedPMID:24685746.

3:LiedtkeMD,TomlinCR,LockhartSM,MillerMM,RathbunRC.Long-termefficacyandsafetyofraltegravirinthemanagementofHIVinfection.InfectDrugResist.2014Mar18;7:73-84.doi:10.2147/IDR.S40168.eCollection2014.Review.PubMedPMID:24672249;PubMedCentralPMCID:PMC3965364.

4:SharmaM,WalmsleySL.RaltegravirasantiretroviraltherapyinHIV/AIDS.ExpertOpinPharmacother.2014Feb;15(3):395-405.doi:10.1517/14656566.2014.868884.Epub2013Dec4.Review.PubMedPMID:24304203.

5:PerryCM.Raltegravir:areviewofitsuseinthemanagementofHIV-1infectioninchildrenandadolescents.PaediatrDrugs.2014Feb;16(1):91-100.doi:10.1007/s40272-013-0058-9.Review.PubMedPMID:24277175.

6:KarmonSL,MarkowitzM.Next-generationintegraseinhibitors:wheretoafterraltegravir?Drugs.2013Mar;73(3):213-28.doi:10.1007/s40265-013-0015-5.Review.PubMedPMID:23413196.

7:LarsonKB,KingJR,AcostaEP.RaltegravirforHIV-1infectedchildrenandadolescents:efficacy,safety,andpharmacokinetics.AdolescHealthMedTher.2013Aug27;4:79-87.doi:10.2147/AHMT.S29462.eCollection2013.Review.PubMedPMID:24600298;PubMedCentralPMCID:PMC3912854.

8:Mateo-CarrascoH,Gálvez-ContrerasMC,Fernández-GinésFD,NguyenTV.ElevatedliverenzymesresultingfromaninteractionbetweenRaltegravirandPanaxginseng:acasereportandbriefreview.DrugMetabolDrugInteract.2012;27(3):171-5.doi:10.1515/dmdi-2012-0019.Review.PubMedPMID:23092794.

9:ShamroeCL,BookstaverPB,RokasKE,WeissmanSB.Updateonraltegravirandthedevelopmentofnewintegrasestrandtransferinhibitors.SouthMedJ.2012Jul;105(7):370-8.doi:10.1097/SMJ.0b013e318258c847.Review.PubMedPMID:22766666.

10:RokasKE,BookstaverPB,ShamroeCL,SuttonSS,MillisorVE,BryantJE,WeissmanSB.RoleofraltegravirinHIV-1management.AnnPharmacother.2012Apr;46(4):578-89.doi:10.1345/aph.1Q616.Epub2012Apr10.Review.PubMedPMID:22496475.

11:BeareKD,CosterMJ,RutledgePJ.DiketoacidinhibitorsofHIV-1integrase:fromL-708,906toraltegravirandbeyond.CurrMedChem.2012;19(8):1177-92.Review.PubMedPMID:22214459.

12:ChaudharyMA,ElbashaEH,KumarRN,NathansonEC.Cost-effectivenessofraltegravirinHIV/AIDS.ExpertRevPharmacoeconOutcomesRes.2011Dec;11(6):627-39.doi:10.1586/erp.11.79.Review.PubMedPMID:22098278.

13:NguyenBY,IsaacsRD,TepplerH,LeavittRY,SklarP,IwamotoM,WenningLA,MillerMD,ChenJ,KempR,XuW,FromtlingRA,VaccaJP,YoungSD,RowleyM,LowerMW,GottesdienerKM,HazudaDJ.Raltegravir:thefirstHIV-1integrasestrandtransferinhibitorintheHIVarmamentarium.AnnNYAcadSci.2011Mar;1222:83-9.doi:10.1111/j.1749-6632.2011.05972.x.Review.PubMedPMID:21434946.

14:First-lineraltegravir.Noevidenceofcomparativeeffectiveness.PrescrireInt.2010Nov;19(110):248-50.Review.PubMedPMID:21284354.

15:BrainardDM,WenningLA,StoneJA,WagnerJA,IwamotoM.Clinicalpharmacologyprofileofraltegravir,anHIV-1integrasestrandtransferinhibitor.JClinPharmacol.2011Oct;51(10):1376-402.doi:10.1177/0091270010387428.Epub2011Jan5.Review.PubMedPMID:21209233.

16:DelaugerreC.[Geneticbarriertoantiretroviraldrug-resistance.Focusonraltegravir,thefirstintegraseinhibitor].MedMalInfect.2010Sep;40Suppl1:S1-10.doi:10.1016/S0399-077X(10)70001-9.Review.French.PubMedPMID:20800182.

17:BurgerDM.Raltegravir:areviewofitspharmacokinetics,pharmacologyandclinicalstudies.ExpertOpinDrugMetabToxicol.2010Sep;6(9):1151-60.doi:10.1517/17425255.2010.513383.Review.PubMedPMID:20701552.

18:ClavelF.HIVresistancetoraltegravir.EurJMedRes.2009Nov24;14Suppl3:47-54.Review.PubMedPMID:19959417;PubMedCentralPMCID:PMC3516824.

19:JohnsonM.Raltegraviruseinspecialpopulations.EurJMedRes.2009Nov24;14Suppl3:43-6.Review.PubMedPMID:19959416;PubMedCentralPMCID:PMC3516827.

20:CossariniF,CastagnaA,LazzarinA.Raltegravirintreatmentnaivepatients.EurJMedRes.2009Nov24;14Suppl3:22-9.Review.PubMedPMID:19959413;PubMedCentralPMCID:PMC3516825.